Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

David Lewis

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Concepts & Ideas

Living Beings

Rats

Genes & Molecular Sequences

Amino Acid Sequence

Anatomy

Liver Microsomes

Physiology

Site-Directed Mutagenesis

Procedures

Sequence Alignment

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
42
Ioannides, Costas
36
Lake, Brian
30
Parke, Dennis
29
Dickins, Maurice
19
Goldfarb, Peter
10
Tarbit, Michael
9
Eddershaw, PJ
6
Ito, Yuko
6
Ayrton, Andrew
5
Jacobs, Miriam
5
Hlavica, Peter
4
Gibson, Gordon
4
Bird, Michael
4
Schulze, J
3
Pelkonen, Olavi

Sign-in to see all Coauthors

Publications

TOP 3
Lewis David F V; Ito Yuko; Lake Brian G
Electronic and structural aspects of p450-mediated drug metabolism.
Pushparajah Daphnee S; Umachandran Meera; Nazir Tariq; Plant Kathryn E; Plant Nick; Lewis David F V; Ioannides Costas
Up-regulation of CYP1A/B in rat lung and liver, and human liver precision-cut slices by a series of polycyclic aromatic hydrocarbons; association with the Ah locus and importance of molecular size.
Ito Yuko; Kondo Hiroki; Goldfarb Peter S; Lewis David F V
Analysis of CYP2D6 substrate interactions by computational methods.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Lewis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lewis David F V; Ito Yuko; Lake Brian G
Electronic and structural aspects of p450-mediated drug metabolism.
Drug metabolism letters 2009;3(2):87-100.
2008: Pushparajah Daphnee S; Umachandran Meera; Nazir Tariq; Plant Kathryn E; Plant Nick; Lewis David F V; Ioannides Costas
Up-regulation of CYP1A/B in rat lung and liver, and human liver precision-cut slices by a series of polycyclic aromatic hydrocarbons; association with the Ah locus and importance of molecular size.
Toxicology in vitro : an international journal published in association with BIBRA 2008;22(1):128-45.
2008: Ito Yuko; Kondo Hiroki; Goldfarb Peter S; Lewis David F V
Analysis of CYP2D6 substrate interactions by computational methods.
Journal of molecular graphics & modelling 2008;26(6):947-56.
2007: Nong A; Charest-Tardif G; Tardif R; Lewis D F V; Sweeney L M; Gargas M L; Krishnan K
Physiologically based modeling of the inhalation pharmacokinetics of ethylbenzene in B6C3F1 mice.
Journal of toxicology and environmental health. Part A 2007;70(21):1838-48.
2007: Lewis David F V; Lake Brian G; Dickins Maurice
Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity.
Journal of enzyme inhibition and medicinal chemistry 2007;22(1):1-6.
2006: Lewis David F V; Lake Brian G; Ito Yuko; Dickins Maurice
Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes.
Journal of enzyme inhibition and medicinal chemistry 2006;21(4):385-9.
2006: Lewis David F V; Ito Yuko; Goldfarb Peter S
Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily.
Current drug metabolism 2006;7(6):589-98.
2006: Lewis David F V; Lake Brian G; Dickins Maurice
Quantitative structure-activity relationships (QSars) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding.
Journal of enzyme inhibition and medicinal chemistry 2006;21(2):127-32.
2006: Lewis David F V; Ito Yuko; Lake Brian G
Metabolism of coumarin by human P450s: a molecular modelling study.
Toxicology in vitro : an international journal published in association with BIBRA 2006;20(2):256-64.
2006: Lewis David F V; Ito Yuko; Goldfarb Peter S
Structural modelling of the human drug-metabolizing cytochromes P450.
Current medicinal chemistry 2006;13(22):2645-52.
2006: Lewis David F V; Lake Brian G; Ito Yuko; Anzenbacher Pavel
Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: the importance of lipophilicity for binding and metabolism.
Drug metabolism and drug interactions 2006;21(3-4):213-31.
2006: Lewis David F V; Dorne Jean-Lou C M
The astronomical pulse of global extinction events.
TheScientificWorldJournal 2006;6():718-26.
2005: Paxton James W; Kestell Philip; Chiang Daniel; Zhou Shufeng; Lewis David F V
Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.
Clinical and experimental pharmacology & physiology 2005;32(8):633-9.
2005: Lewis David F V
Human P450s in the metabolism of drugs: molecular modelling of enzyme-substrate interactions.
Expert opinion on drug metabolism & toxicology 2005;1(1):5-8.
2005: Lewis David F V; Lake Brian G; Bird Michael G
Molecular modelling of human microsomal epoxide hydrolase (EH) by homology with a fungal (Aspergillus niger) EH crystal structure of 1.8 A resolution: structure-activity relationships in epoxides inhibiting EH activity.
Toxicology in vitro : an international journal published in association with BIBRA 2005;19(4):517-22.
2004: Lewis D F V; Lake B G; Dickins M; Goldfarb P S
Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(6):549-69.
2004: Lewis David F V; Lake Brian G; Dickins M
Quantitative structure-activity relationships within a homologous series of 7-alkoxyresorufins exhibiting activity towards CYP1A and CYP2B enzymes: molecular modelling studies on key members of the resorufin series with CYP2C5-derived models of human CYP1A1, CYP1A2, CYP2B6 and CYP3A4.
Xenobiotica; the fate of foreign compounds in biological systems 2004;34(6):501-13.
2004: Lewis David F V; Jacobs Miriam N; Dickins Maurice
Compound lipophilicity for substrate binding to human P450s in drug metabolism.
Drug discovery today 2004;9(12):530-7.
2004: Lewis David F V
57 varieties: the human cytochromes P450.
Pharmacogenomics 2004;5(3):305-18.
2004: Lewis David F V
Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes.
Toxicology in vitro : an international journal published in association with BIBRA 2004;18(1):89-97.
2004: Lewis David F V
Hydrogen bonding in human p450-substrate interactions: a major contribution to binding affinity.
TheScientificWorldJournal 2004;4():1074-82.
2004: Ioannides Costas; Lewis David F V
Cytochromes P450 in the bioactivation of chemicals.
Current topics in medicinal chemistry 2004;4(16):1767-88.
2004: Lewis David F V; Lake Brian G; Dickins Maurice
Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism.
Drug metabolism and drug interactions 2004;20(3):111-42.
2003: Lewis David F V
On the estimation of binding affinity (deltaGbind) for human P450 substrates (based on Km and KD values).
Current drug metabolism 2003;4(5):331-40.
2003: Lewis David F V
Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families.
Current medicinal chemistry 2003;10(19):1955-72.
2003: Salonen Jarmo S; Nyman Leena; Boobis Alan R; Edwards Robert J; Watts Patricia; Lake Brian G; Price Roger J; Renwick Anthony B; Gómez-Lechón Maria-Jose; Castell José V; Ingelman-Sundberg Magnus; Hidestrand Mats; Guillouzo Andre; Corcos Laurent; Goldfarb Peter S; Lewis David F V; Taavitsainen Päivi; Pelkonen Olavi
Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1093-102.
2003: Hlavica P; Schulze J; Lewis D F V
Functional interaction of cytochrome P450 with its redox partners: a critical assessment and update of the topology of predicted contact regions.
Journal of inorganic biochemistry 2003;96(2-3):279-97.
2003: Don Ming-Jaw; Lewis David F V; Wang Shu-Yun; Tsai Mei-Wen; Ueng Yune-Fang
Effect of structural modification on the inhibitory selectivity of rutaecarpine derivatives on human CYP1A1, CYP1A2, and CYP1B1.
Bioorganic & medicinal chemistry letters 2003;13(15):2535-8.
2003: Lewis David F V
P450 structures and oxidative metabolism of xenobiotics.
Pharmacogenomics 2003;4(4):387-95.
2003: Lewis David F V
Structural models for cytochrome P450-mediated catalysis.
TheScientificWorldJournal 2003;3():536-45.
2003: Lewis David F V; Gillam Elizabeth M J; Everett Steven A; Shimada Tsutomu
Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism.
Chemico-biological interactions 2003;145(3):281-95.
2003: Lewis D F V; Lake B G; Dickins M; Goldfarb P S
Homology modelling of CYP2A6 based on the CYP2C5 crystallographic template: enzyme-substrate interactions and QSARs for binding affinity and inhibition.
Toxicology in vitro : an international journal published in association with BIBRA 2003;17(2):179-90.
2003: Lewis D F V; Lake B G; Dickins M; Ueng Y-F; Goldfarb P S
Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure.
Xenobiotica; the fate of foreign compounds in biological systems 2003;33(3):239-54.
2003: Jacobs M N; Dickins M; Lewis D F V
Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure.
The Journal of steroid biochemistry and molecular biology 2003;84(2-3):117-32.
2003: Lewis David F V; Dickins Maruice
Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism.
Drug metabolism reviews 2003;35(1):1-18.
2003: Lewis D F V; Lake B G; Bird M G; Loizou G D; Dickins M; Goldfarb P S
Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions.
Toxicology in vitro : an international journal published in association with BIBRA 2003;17(1):93-105.
2003: Lewis David F V
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
Archives of biochemistry and biophysics 2003;409(1):32-44.
2003: Lewis David F V
Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s.
Inflammopharmacology 2003;11(1):43-73.
2003: Lewis David F V; Dickins Maurice; Lake Brian G; Goldfarb Peter S
Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
Drug metabolism and drug interactions 2003;19(4):257-85.
2003: Lewis David F V; Dickins Maurice; Lake Brian G; Goldfarb Peter S
A molecular model of CYP2D6 constructed by homology with the CYP2C5 crystallographic template: investigation of enzyme-substrate interactions.
Drug metabolism and drug interactions 2003;19(3):189-210.
2003: Lewis David F V; Sams Craig; Loizou George D
A quantitative structure-activity relationship analysis on a series of alkyl benzenes metabolized by human cytochrome p450 2E1.
Journal of biochemical and molecular toxicology 2003;17(1):47-52.
2003: Lewis David F V; Ioannides Costas; Parke Dennis V
A quantitative structure-activity relationship (QSAR) study of mutagenicity in several series of organic chemicals likely to be activated by cytochrome P450 enzymes.
Teratogenesis, carcinogenesis, and mutagenesis 2003;Suppl 1():187-93.
2002: Lewis D F V; Ogg M S; Goldfarb P S; Gibson G G
Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor alpha (hERalpha) LBD: quantitative structure-activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement.
The Journal of steroid biochemistry and molecular biology 2002;82(2-3):195-9.
2002: Lewis David F V; Dickins Maurice
Substrate SARs in human P450s.
Drug discovery today 2002;7(17):918-25.
2002: Lewis David F V
Modelling human cytochromes P450 involved in drug metabolism from the CYP2C5 crystallographic template.
Journal of inorganic biochemistry 2002;91(4):502-14.
2002: Lewis D F V; Lake B G
Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(7):547-61.
2002: Lewis D F V; Jacobs M N; Dickins M; Lake B G
Quantitative structure--activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families.
Toxicology 2002;176(1-2):51-7.
2002: Lewis David F V; Broughton Howard B
Molecular binding interactions: their estimation and rationalization in QSARs in terms of theoretically derived parameters.
TheScientificWorldJournal 2002;2():1776-802.
2002: Lewis D F V; Jacobs M N; Dickins M; Lake B G
Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR gamma crystal structure.
Toxicology in vitro : an international journal published in association with BIBRA 2002;16(3):275-80.
2002: Lewis D F V
Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(4):305-23.
2002: Jacobs Miriam N; Lewis David F V
Steroid hormone receptors and dietary ligands: a selected review.
The Proceedings of the Nutrition Society 2002;61(1):105-22.
2002: Lewis David F V; Modi Sandeep; Dickins Maurice
Structure-activity relationship for human cytochrome P450 substrates and inhibitors.
Drug metabolism reviews 2002;34(1-2):69-82.
2002: Lewis David F V
Molecular modeling of human cytochrome P450-substrate interactions.
Drug metabolism reviews 2002;34(1-2):55-67.
2002: Lewis D F V; Dickins M
Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s.
Toxicology 2002;170(1-2):45-53.
2002: Lewis David F V; Lake Brian G; Dickins Maurice; Goldfarb Peter S
Molecular modelling of CYP2B6 based on homology with the CYP2C5 crystal structure: analysis of enzyme-substrate interactions.
Drug metabolism and drug interactions 2002;19(2):115-35.
2002: Lewis David F V; Bailey Paul T; Low Lawrence K
Molecular modelling of the mouse cytochrome P450 CYP2F2 based on the CYP102 crystal structure template and selective CYP2F2 substrate interactions.
Drug metabolism and drug interactions 2002;19(2):97-113.
2002: Lewis D F V; Gorrod J W
Molecular orbital calculations and nicotine metabolism: a rationale for experimentally observed metabolite ratios.
Drug metabolism and drug interactions 2002;19(1):29-39.
2002: Lewis D F V
Modelling human cytochrome P450-substrate interactions.
Ernst Schering Research Foundation workshop 2002;(37):235-48.
2001: Skene D J; Papagiannidou E; Hashemi E; Snelling J; Lewis D F; Fernandez M; Ioannides C
Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices.
Journal of pineal research 2001;31(4):333-42.
2001: Lewis D F; Dickins M
Quantitative structure-activity relationships (QSARs) within series of inhibitors for mammalian cytochromes P450 (CYPs).
Journal of enzyme inhibition 2001;16(4):321-30.
2001: Hlavica P; Lewis D F
Allosteric phenomena in cytochrome P450-catalyzed monooxygenations.
European journal of biochemistry / FEBS 2001;268(18):4817-32.
2001: Pelkonen O; Myllynen P; Taavitsainen P; Boobis A R; Watts P; Lake B G; Price R J; Renwick A B; Gómez-Lechón M J; Castell J V; Ingelman-Sundberg M; Hidestrand M; Guillouzo A; Corcos L; Goldfarb P S; Lewis D F
Carbamazepine: a 'blind' assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems.
Xenobiotica; the fate of foreign compounds in biological systems 2001;31(6):321-43.
2001: Andersson T B; Sjöberg H; Hoffmann K J; Boobis A R; Watts P; Edwards R J; Lake B G; Price R J; Renwick A B; Gómez-Lechón M J; Castell J V; Ingelman-Sundberg M; Hidestrand M; Goldfarb P S; Lewis D F; Corcos L; Guillouzo A; Taavitsainen P; Pelkonen O
An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):712-20.
2001: Lewis D F; Sheridan G
Cytochromes P450, oxygen, and evolution.
TheScientificWorldJournal 2001;1():151-67.
2001: Lewis D F; Modi S; Dickins M
Quantitative structure-activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism.
Drug metabolism and drug interactions 2001;18(3-4):221-42.
2000: Lewis D F; Ioannides C; Parke D V; Schulte-Hermann R
Quantitative structure-activity relationships in a series of endogenous and synthetic steroids exhibiting induction of CYP3A activity and hepatomegaly associated with increased DNA synthesis.
The Journal of steroid biochemistry and molecular biology 2000;74(4):179-85.
2000: Lewis D F
Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.
Toxicology 2000;144(1-3):197-203.
2000: Lehnerer M; Schulze J; Achterhold K; Lewis D F; Hlavica P
Identification of key residues in rabbit liver microsomal cytochrome P450 2B4: importance in interactions with NADPH-cytochrome P450 reductase.
Journal of biochemistry 2000;127(1):163-9.
2000: Lewis D F; Bird M G; Dickins M; Lake B G; Eddershaw P J; Tarbit M H; Goldfarb P S
Molecular modelling of human CYP2E1 by homology with the CYP102 haemoprotein domain: investigation of the interactions of substrates and inhibitors within the putative active site of the human CYP2E1 isoform.
Xenobiotica; the fate of foreign compounds in biological systems 2000;30(1):1-25.
2000: Lewis D F
Modelling human cytochromes P450 for evaluating drug metabolism: an update.
Drug metabolism and drug interactions 2000;16(4):307-24.
1999: Lewis D F; Lake B G; George S G; Dickins M; Eddershaw P J; Tarbit M H; Beresford A P; Goldfarb P S; Guengerich F P
Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102.
Toxicology 1999;139(1-2):53-79.
1999: Lewis D F; Lake B G
Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102.
Xenobiotica; the fate of foreign compounds in biological systems 1999;29(8):763-81.
1999: Lewis D F
Frontier orbitals in chemical and biological activity: quantitative relationships and mechanistic implications.
Drug metabolism reviews 1999;31(3):755-816.
1999: Lewis D F
Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie 1999;51(4-5):369-74.
1999: Lewis D F; Lake B G; Dickins M; Eddershaw P J; Tarbit M H; Goldfarb P S
Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4.
Xenobiotica; the fate of foreign compounds in biological systems 1999;29(4):361-93.
1999: Lewis D F; Dickins M; Lake B G; Eddershaw P J; Tarbit M H; Goldfarb P S
Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity.
Toxicology 1999;133(1):1-33.
1999: Lewis D F; Dickins M; Eddershaw P J; Tarbit M H; Goldfarb P S
Cytochrome P450 substrate specificities, substrate structural templates and enzyme active site geometries.
Drug metabolism and drug interactions 1999;15(1):1-49.
1999: Lewis D F; Wiseman A; Tarbit M H
Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Journal of enzyme inhibition 1999;14(3):175-92.
1998: Lewis D F; Pratt J M
The P450 catalytic cycle and oxygenation mechanism.
Drug metabolism reviews 1998;30(4):739-86.
1998: Lewis D F; Ioannides C; Parke D V
An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation.
Drug metabolism reviews 1998;30(4):709-37.
1998: Lewis D F; Eddershaw P J; Dickins M; Tarbit M H; Goldfarb P S
Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate.
Chemico-biological interactions 1998;115(3):175-99.
1998: Lewis D F; Ioannides C; Parke D V
A combined COMPACT and HazardExpert study of 40 chemicals for which information on mutagenicity and carcinogenicity is known, including the results of human epidemiological studies.
Human & experimental toxicology 1998;17(10):577-86.
1998: Lewis D F; Ioannides C; Parke D V
Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen.
Environmental health perspectives 1998;106(10):633-41.
1998: Lewis D F; Lee-Robichaud P
Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure.
The Journal of steroid biochemistry and molecular biology 1998;66(4):217-33.
1998: Lehnerer M; Schulze J; Pernecky S J; Lewis D F; Eulitz M; Hlavica P
Influence of mutation of the amino-terminal signal anchor sequence of cytochrome P450 2B4 on the enzyme structure and electron transfer processes.
Journal of biochemistry 1998;124(2):396-403.
1998: Lewis D F
The CYP2 family: models, mutants and interactions.
Xenobiotica; the fate of foreign compounds in biological systems 1998;28(7):617-61.
1998: Lewis D F; Watson E; Lake B G
Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics.
Mutation research 1998;410(3):245-70.
1998: Schulze J; Lehnerer M; Lewis D F; Hlavica P
Amino acid residue 250 has a functional role in the assembly of rabbit liver microsomal cytochrome P450 2B4.
Biochemistry and molecular biology international 1998;44(6):1147-55.
1998: Lewis D F; Dickins M; Weaver R J; Eddershaw P J; Goldfarb P S; Tarbit M H
Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily.
Xenobiotica; the fate of foreign compounds in biological systems 1998;28(3):235-68.
1998: Lewis D F; Lake B G
Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes.
Toxicology 1998;125(1):31-44.
1998: Lewis D F; Ioannides C; Parke D V
Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals.
Mutation research 1998;412(1):41-54.
1997: Lewis D F; Brantom P G; Ioannides C; Walker R; Parke D V
Nitrosamine carcinogenesis: rodent assays, quantitative structure-activity relationships, and human risk assessment.
Drug metabolism reviews 1997;29(4):1055-78.
1997: Lewis D F
Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1).
Drug metabolism reviews 1997;29(3):589-650.
1997: Lewis D F; Lake B G
Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners.
Xenobiotica; the fate of foreign compounds in biological systems 1997;27(5):443-78.
1997: Lewis D F; Eddershaw P J; Goldfarb P S; Tarbit M H
Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.
Xenobiotica; the fate of foreign compounds in biological systems 1997;27(4):319-39.
1997: Cheung Y L; Lewis D F; Ridd T I; Gray T J; Ioannides C
Diaminonaphthalenes and related aminocompounds: mutagenicity, CYP1A induction and interaction with the Ah receptor.
Toxicology 1997;118(2-3):115-27.
1997: Lewis D F; Bird M G; Parke D V
Molecular modelling of CYP2E1 enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity.
Toxicology 1997;118(2-3):93-113.
1996: Lewis D F; Ioannides C; Parke D V
COMPACT and molecular structure in toxicity assessment: a prospective evaluation of 30 chemicals currently being tested for rodent carcinogenicity by the NCI/NTP.
Environmental health perspectives 1996;104 Suppl 5():1011-6.
1996: Lewis D F; Eddershaw P J; Goldfarb P S; Tarbit M H
Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals.
Xenobiotica; the fate of foreign compounds in biological systems 1996;26(10):1067-86.
1996: Lewis D F; Langley G R
A validation study of the COMPACT and HazardExpert techniques with 40 chemicals.
Mutation research 1996;369(3-4):157-74.
1996: Lewis D F; Lake B G
Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues.
Xenobiotica; the fate of foreign compounds in biological systems 1996;26(7):723-53.
1995: Lewis D F; Lake B G; Parke D V
Molecular orbital-generated QSARs in a homologous series of alkoxyresorufins and studies of their interactive docking with P450s.
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(12):1355-69.
1995: Boyd G W; Coombs M M; Ioannides C; Lewis D F; Snelling J; Tsakalof A
Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen.
Carcinogenesis 1995;16(10):2351-5.
1995: Ayalogu E O; Snelling J; Lewis D F; Talwar S; Clifford M N; Ioannides C
Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locus.
Biochimica et biophysica acta 1995;1272(2):89-94.
1995: Lewis D F; Ioannides C; Parke D V
A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation rates.
Biochemical pharmacology 1995;50(5):619-25.
1995: Lewis D F; Lake B G
Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity.
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(6):585-98.
1995: Lewis D F; Parke D V
The genotoxicity of benzanthracenes: a quantitative structure-activity study.
Mutation research 1995;328(2):207-14.
1995: Lewis D F
Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3).
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(4):333-66.
1995: Lewis D F; Ioannides C; Parke D V
A retrospective evaluation of COMPACT predictions of the outcome of NTP rodent carcinogenicity testing.
Environmental health perspectives 1995;103(2):178-84.
1995: Lewis D F; Ioannides C; Parke D V
Computer graphics analysis of the interaction of alkoxy methylenedioxybenzenes with cytochromes P4501.
Toxicology letters 1995;76(1):39-45.
1994: Lewis D F
Comparison between rodent carcinogenicity test results of 44 chemicals and a number of predictive systems.
Regulatory toxicology and pharmacology : RTP 1994;20(3 Pt 1):215-22.
1994: Lewis D F; Ioannides C; Walker R; Parke D V
Safety evaluations of food chemicals by "COMPACT". 1. A study of some acyclic terpenes.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1994;32(11):1053-9.
1994: Lewis D F; Lake B G; Ioannides C; Parke D V
Inhibition of rat hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxy coumarins: QSAR studies.
Xenobiotica; the fate of foreign compounds in biological systems 1994;24(9):829-38.
1994: Ioannides C; Lewis D F; Parke D V
The use of computers in the safety evaluation of drugs and other chemicals.
European journal of drug metabolism and pharmacokinetics 1994;19(3):225-33.
1994: Lewis D F; Ioannides C; Parke D V
Molecular modelling of cytochrome CYP1A1: a putative access channel explains differences in induction potency between the isomers benzo(a)pyrene and benzo(e)pyrene, and 2- and 4-acetylaminofluorene.
Toxicology letters 1994;71(3):235-43.
1994: Lewis D F; Ioannides C; Parke D V
Interaction of a series of nitriles with the alcohol-inducible isoform of P450: computer analysis of structure-activity relationships.
Xenobiotica; the fate of foreign compounds in biological systems 1994;24(5):401-8.
1994: Rekka E; Ayalogu E O; Lewis D F; Gibson G G; Ioannides C
Induction of hepatic microsomal CYP4A activity and of peroxisomal beta-oxidation by two non-steroidal anti-inflammatory drugs.
Archives of toxicology 1994;68(2):73-8.
1994: Lewis D F; Moereels H; Lake B G; Ioannides C; Parke D V
Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D.
Drug metabolism reviews 1994;26(1-2):261-85.
1993: Ioannides C; Cheung Y L; Wilson J; Lewis D F; Gray T J
The mutagenicity and interactions of 2- and 4-(acetylamino)fluorene with cytochrome P450 and the aromatic hydrocarbon receptor may explain the difference in their carcinogenic potency.
Chemical research in toxicology 1993;6(4):535-41.
1993: Lewis D F; Ioannides C; Parke D V
Validation of a novel molecular orbital approach (COMPACT) for the prospective safety evaluation of chemicals, by comparison with rodent carcinogenicity and Salmonella mutagenicity data evaluated by the U.S. NCI/NTP.
Mutation research 1993;291(1):61-77.
1993: Lewis D F; Lake B G
Interaction of some peroxisome proliferators with the mouse liver peroxisome proliferator-activated receptor (PPAR): a molecular modelling and quantitative structure-activity relationship (QSAR) study.
Xenobiotica; the fate of foreign compounds in biological systems 1993;23(1):79-96.
1993: Ioannides C; Ayrton A D; Lewis D F; Walker R
Extrapolation of in vitro antimutagenicity to the in vivo situation: the case for anthraflavic acid.
Basic life sciences 1993;61():103-10.
1992: Ayrton A D; Lewis D F; Walker R; Ioannides C
Antimutagenicity of ellagic acid towards the food mutagen IQ: investigation into possible mechanisms of action.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 1992;30(4):289-95.
1990: Lewis D F; Ioannides C; Parke D V
A retrospective study of the molecular toxicology of benoxaprofen.
Toxicology 1990;65(1-2):33-47.
1990: Lewis D F; Ioannides C; Parke D V
A prospective toxicity evaluation (COMPACT) on 40 chemicals currently being tested by the National Toxicology Program.
Mutagenesis 1990;5(5):433-5.
1990: Cottrell S; Hartman G C; Lewis D F; Parke D V
Studies on the cytochrome P-450 of avocado (Persea [corrected] americana) mesocarp microsomal fraction.
Xenobiotica; the fate of foreign compounds in biological systems 1990;20(7):711-26.
1990: Ioannides C; Ayrton A D; Keele A; Lewis D F; Flatt P R; Walker R
Mechanism of the in vitro antimutagenic action of retinol.
Mutagenesis 1990;5(3):257-62.
1990: Smith J N; Ayrton A D; Chown J; Lewis D F; Ioannides C
Feprazone: an inducer of the P450 II B family of proteins in the rat.
Journal of biochemical toxicology 1990;5(1):9-12.
1990: Parke D V; Ioannides C; Lewis D F; Obrebska-Parke M J
Current problems in the evaluation of chemical safety.
Polish journal of occupational medicine 1990;3(1):15-41.
1989: Brown L P; Lewis D F; Flint O P; Orton T C; Gibson G G
Teratogenicity of phenylhydantoins in an in vitro system: molecular orbital-generated quantitative structure-toxicity relationships.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(12):1471-81.
1989: Sharma R K; Doig M V; Lewis D F; Gibson G G
Role of hepatic and renal cytochrome P-450 IVA1 in the metabolism of lipid substrates.
Biochemical pharmacology 1989;38(20):3621-9.
1989: Ioannides C; Lewis D F; Trinick J; Neville S; Sertkaya N N; Kajbaf M; Gorrod J W
A rationale for the non-mutagenicity of 2- and 3-aminobiphenyls.
Carcinogenesis 1989;10(8):1403-7.
1989: Rodrigues A D; Ayrton A D; Williams E J; Lewis D F; Walker R; Ioannides C
Preferential induction of the rat hepatic P450 I proteins by the food carcinogen 2-amino-3-methyl-imidazo[4,5-f]quinoline.
European journal of biochemistry / FEBS 1989;181(3):627-31.
1989: Lewis D F
Molecular orbital calculations on tumour-inhibitory phenyl aziridines: QSARs.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(3):341-56.
1989: Lewis D F
Molecular orbital calculations on tumour-inhibitory aniline mustards: QSARs.
Xenobiotica; the fate of foreign compounds in biological systems 1989;19(2):243-51.
1989: Lewis D F; Ioannides C; Parke D V
Prediction of chemical carcinogenicity from molecular and electronic structures: a comparison of MINDO/3 and CNDO/2 molecular orbital methods.
Toxicology letters 1989;45(1):1-13.
1989: Lewis D F; Ioannides C; Parke D V
Molecular orbital studies of oxygen activation and mechanisms of cytochromes P-450-mediated oxidative metabolism of xenobiotics.
Chemico-biological interactions 1989;70(3-4):263-80.
1989: Lewis D F; Rodrigues A D; Ioannides C; Parke D V
Adverse reactions of imidazole antifungal agents: computer graphic studies of cytochrome P-450 interactions.
Journal of biochemical toxicology 1989;4(4):231-4.
1988: Parke D V; Ioannides C; Lewis D F
Metabolic activation of carcinogens and toxic chemicals.
Human toxicology 1988;7(5):397-404.
1987: Ayrton A D; Lewis D F; Ioannides C; Walker R
Anthraflavic acid is a potent and specific inhibitor of cytochrome P-448 activity.
Biochimica et biophysica acta 1987;916(3):328-31.
1987: Lewis D F
Molecular orbital calculations and quantitative structure-activity relationships for some polyaromatic hydrocarbons.
Xenobiotica; the fate of foreign compounds in biological systems 1987;17(11):1351-61.
1987: Rodrigues A D; Lewis D F; Ioannides C; Parke D V
Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450.
Xenobiotica; the fate of foreign compounds in biological systems 1987;17(11):1315-27.
1987: Lewis D F; Ioannides C; Parke D V
Structural requirements for substrates of cytochromes P-450 and P-448.
Chemico-biological interactions 1987;64(1-2):39-60.

Sign-in to see more